$7.38
-0.33-4.28%
Last update: Nov 6, 7:05 AM

Regenxbio (RGNX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.31 | $0.12 | $-1.40 | $-0.91 |
| Actual | $-0.62 | $0.43 | $-1.72 | $-1.30 |
| Surprise | +52.7% | +258.3% | -22.9% | -42.9% |
| Revenue | ||||
| Estimate | $10.5M | $104.1M | $25.0M | $39.9M |
| Actual | $9.2M | $108.0M | $6.4M | $30.3M |
| Surprise | -12.5% | +3.76% | -74.4% | -23.9% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.01 | $-1.04 | $-0.98 | $-0.85 |
| Revenue | ||||
| Consensus | $26.3M | — | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.62 | $-1.31 | 52.7 % |
| Q2 | Aug 6, 2026 | $0.43 | $0.12 | 258.3 % |
| Q1 | May 14, 2026 | $-1.72 | $-1.40 | -22.9 % |
| Q4 | Mar 5, 2026 | $-1.30 | $-0.91 | -42.9 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $9.16M | $10.47M | -12.5 % |
| Q2 | Aug 6, 2026 | $108.02M | $104.10M | 3.76 % |
| Q1 | May 14, 2026 | $6.39M | $24.96M | -74.4 % |
| Q4 | Mar 5, 2026 | $30.34M | $39.88M | -23.9 % |